BEAM logo

Beam Therapeutics Inc.

BEAM
Healthcare|Biotechnology|US
$26.41
+0.54 (+2.09%)
Tangible Book / Share
$9.10
Cash / Share
$9.97

About

Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States. The company's developmental portfolio features several key candidates: BEAM-101 is being advanced to treat both sickle cell disease and beta thalassemia. BEAM-102 is specifically designed for addressing sickle cell disease. BEAM-201, an allogeneic chimeric antigen receptor T-cell therapy, is under investigation for individuals suffering from relapsed or refractory T-cell acute lymphoblastic leukemia. BEAM-301 is a liver-targeted candidate aimed at patients afflicted with Glycogen Storage Disease Type Ia. Beyond these flagship programs, Beam Therapeutics is also engaged in devising treatments for alpha-1 antitrypsin deficiency, various ocular conditions, and other disorders impacting the liver, muscular system, and central nervous system. To further its research and development objectives, Beam Therapeutics has forged numerous strategic alliances and partnerships. These include collaborations with Boston Children's Hospital; a research and clinical trial agreement with Magenta Therapeutics, Inc.; a licensing deal with Sana Biotechnology, Inc.; and a research partnership with the Institute of Molecular and Clinical Ophthalmology Basel. Additionally, the company maintains research collaborations with both Pfizer Inc. and Apellis Pharmaceuticals, Inc., alongside a comprehensive collaboration and license agreement with Verve Therapeutics, Inc.

Stock Price

+14.1%(1Y)
1M
+7.4%
3M
-3.9%
6M
-18.3%
YTD
-4.7%
1Y
+22.0%
3Y
+15.3%
5Y
-73.3%

Pipeline Summary

15 total trials
6
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
Recruiting: 7Active: 5By Invitation: 1Completed: 2

Active Trials (12)

Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma
NCT06934382T-Cell Acute Lymphoblastic Leukemia/Lymphoma
Phase 1Recruiting
Enrollment: 33 participants
A Long-term Follow-up Study in Patients Who Received BEAM-101
NCT07373639Hemoglobinopathy
Recruiting
Enrollment: 50 participants
BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease
NCT05456880Sickle Cell Disease
Phase 1Phase 2Active
Enrollment: 15 participants
A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)
NCT06389877Alpha 1-Antitrypsin Deficiency
Phase 1Phase 2Recruiting
Enrollment: 192 participants
Achieving Understanding of the Natural History of Sickle Cell Trait (AUNT)
NCT06071377Sickle Cell Trait
Recruiting
Enrollment: 1,000 participants

BioScore

4.6/10
Cautious

Key Facts

Market Cap$2.73B
Employees511 (+6% YoY)
CEOJohn Evans
IPO DateFeb 6, 2020
Beta2.22
52-Week Range$20.23 – $38.26
Avg Volume1,961,120
ExchangeNASDAQ
Websitebeamtx.com

Ownership

Float85.3%
Shares Outstanding103.3M

Recent Insider Trades

Evans John M.OPTION EX.
Oct 16, 202625,000 shares @ $1.03
Evans John M.SELL
Oct 15, 202625,000 shares @ $23.57
Evans John M.SELL
Oct 16, 202625,000 shares @ $23.98
Evans John M.OPTION EX.
Oct 15, 202625,000 shares @ $1.03
Evans John M.OPTION EX.
Oct 16, 202625,000 shares @ $1.03

Peers

ALLOAllogene Therapeutics, Inc.
$359.3M
CLLSCellectis S.A.
$107.8M
CRBUCaribou Biosciences, Inc.
$48.1M
CRSPCRISPR Therapeutics AG
$4.86B
DTILPrecision BioSciences, Inc.
$292.6M
EDITEditas Medicine, Inc.
$394.7M
FATEFate Therapeutics, Inc.
$213.9M
NTLAIntellia Therapeutics, Inc.
$1.59B
Data last updated: Nov 9, 2026, 03:59 AM